Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Income from Continuing Operations for 10 consecutive years, with 47505000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 9.73% to 47505000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 196539000.0, a 24.59% increase, with the full-year FY2025 number at 196539000.0, up 24.58% from a year prior.
  • Income from Continuing Operations was 47505000.0 for Q4 2025 at Rhythm Pharmaceuticals, up from 52904000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 32261000.0 in Q2 2024 to a low of 141372000.0 in Q1 2024.
  • A 5-year average of 49983000.0 and a median of 45727000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 171.08% in 2024, then soared 64.99% in 2025.
  • Rhythm Pharmaceuticals' Income from Continuing Operations stood at 50855000.0 in 2021, then increased by 16.44% to 42493000.0 in 2022, then rose by 2.02% to 41633000.0 in 2023, then dropped by 3.98% to 43292000.0 in 2024, then decreased by 9.73% to 47505000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Income from Continuing Operations are 47505000.0 (Q4 2025), 52904000.0 (Q3 2025), and 46632000.0 (Q2 2025).